Since 2015, Discern has served as an advisor and subject matter expert for Biogen’s ongoing Multiple Sclerosis (MS) quality and performance measurement initiative. Using a multi-pronged approach to measure development, implementation, and quality improvement, Discern has coordinated activities among stakeholders through Biogen’s MS Quality Steering Committee, as well as with national healthcare organizations including the Pharmacy Quality Alliance (PQA) and the National Quality Forum (NQF). Through this collaboration, four MS measures have been developed by PQA and are being prepared for field testing through four MS centers by the MS-Continuous Quality Improvement (MS-CQI) Collaborative. One measure is focused on the use of Disease Modifying Therapy (DMT) and three measures focus on Magnetic Resonance Imaging (MRI) for MS care and treatment monitoring. Once the measures are finalized, Discern will assist in promoting uptake of the measures through implementation in federal programs. Separately, the NQF Measure IncubatorTM has been engaged to focus on development of an MS Patient Reported Outcome-Performance Measure (PRO-PM). The goal of the ongoing Discern/Biogen partnership is improved care for patients with MS.